1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Autor:	F. Saad, A.J. Armstrong, A. Thiery-Vuillemin, M. Oya, N.D. Shore, G. Procopio, C. Arslan, N. Mehra, F. Parnis, E. Brown, F. Constans Schlurmann, J.Y. Joung, M. Sugimoto, O. Sartor, Y-Z. Liu, C.H. Poehlein, C. Desai, P.M.D. Del Rosario, N. Clarke
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S1160
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a0bb3da953aea5cd6b583778c2a6fb11 https://doi.org/10.1016/j.annonc.2022.07.1945 Zobrazit plný text záznamu